Skip to main navigation Skip to search Skip to main content

CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

  • Xiaoyi Hu
  • , Asiri Ediriwickrema
  • , Atif Saleem
  • , Brent Tan
  • , Naveen Pemmaraju
  • , Gabriel N. Mannis

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Article number107479
JournalLeukemia Research
Volume139
DOIs
StatePublished - Apr 2024

Keywords

  • BPDCN
  • CD123
  • Daratumumab
  • Tagraxofusp
  • Venetoclax

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this